chr3-46859496-G-A
Variant summary
Our verdict is Pathogenic. Variant got 10 ACMG points: 10P and 0B. PM1PM2PM5PP3_Strong
The NM_000258.3(MYL3):c.460C>T(p.Arg154Cys) variant causes a missense change. The variant allele was found at a frequency of 0.000013 in 1,614,108 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R154H) has been classified as Pathogenic.
Frequency
Consequence
NM_000258.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 10 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MYL3 | NM_000258.3 | c.460C>T | p.Arg154Cys | missense_variant | 4/7 | ENST00000292327.6 | NP_000249.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MYL3 | ENST00000292327.6 | c.460C>T | p.Arg154Cys | missense_variant | 4/7 | 1 | NM_000258.3 | ENSP00000292327 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000394 AC: 6AN: 152232Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000159 AC: 4AN: 251410Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135884
GnomAD4 exome AF: 0.0000103 AC: 15AN: 1461876Hom.: 0 Cov.: 32 AF XY: 0.00000825 AC XY: 6AN XY: 727240
GnomAD4 genome AF: 0.0000394 AC: 6AN: 152232Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74366
ClinVar
Submissions by phenotype
Hypertrophic cardiomyopathy Uncertain:3
Uncertain significance, no assertion criteria provided | research | Agnes Ginges Centre for Molecular Cardiology, Centenary Institute | Apr 07, 2020 | This variant has been identified as part of our research program. Refer to the 'condition' field for the phenotype of the proband identified with this variant. For further information please feel free to contact us. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 08, 2024 | This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 154 of the MYL3 protein (p.Arg154Cys). This variant is present in population databases (rs143852164, gnomAD 0.004%). This missense change has been observed in individuals with hypertrophic cardiomyopathy (PMID: 23283745, 25351510, 27532257, 31110529). ClinVar contains an entry for this variant (Variation ID: 43124). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. This variant disrupts the p.Arg154 amino acid residue in MYL3. Other variant(s) that disrupt this residue have been observed in individuals with MYL3-related conditions (PMID: 28408708), which suggests that this may be a clinically significant amino acid residue. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | All of Us Research Program, National Institutes of Health | Dec 18, 2023 | This missense variant replaces arginine with cysteine at codon 154 of the MYL3 protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in individuals affected with hypertrophic cardiomyopathy (PMID: 23283745, 23396983, 27532257, 31110529, 33495597). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
not specified Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Apr 13, 2015 | Variant classified as Uncertain Significance - Favor Pathogenic. The p.Arg154Cys variant in MYL3 has been previously reported in 1 heterozygous Chinese individu al with HCM (Zou 2013). This variant has also been identified by our laboratory in 1 homozygous Bangladeshi infant with RCM, 1 heterozygous African American adu lt with HCM, and in 1 heterozygous Iranian adult with HCM, and was found to segr egate with disease in 1 heterozygous affected relative. This variant has also be en identified in 1/67688 European chromosomes by the Exome Aggregation Consortiu m (ExAC, http://exac.broadinstitute.org; dbSNP rs143852164). Computational predi ction tools and conservation analysis suggest that this variant may impact the p rotein, though this information is not predictive enough to determine pathogenic ity. In addition, a different amino acid change at this position (p.Arg154His) h as also been reported in several individuals with HCM (Poetter 1996, LMM unpubli shed data), supporting that a change at this position may not be tolerated. In s ummary, while there is some suspicion for a pathogenic role, the clinical signif icance of the p.Arg154Cys variant is uncertain. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jan 28, 2021 | Variant summary: MYL3 c.460C>T (p.Arg154Cys) results in a non-conservative amino acid change located in the EF-hand domain (IPR002048) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 1.6e-05 in 251410 control chromosomes (gnomAD v2.1). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.460C>T has been reported in the literature in individuals affected with Hypertrophic Cardiomyopathy (HCM), however, in most of these cases without strong evidence for causality (e.g. Zou_2013, Lopes_2013, Wang_2014, Walsh_2017). The variant was also reported to be found in large scale population based sequencing projects, but no phenotype was provided for these individuals (Amendola_2015, Narang_2020). These reports therefore do not provide unequivocal conclusions about association of the variant with Hypertrophic Cardiomyopathy. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. A different missense variant affecting the same amino acid residue (R154H) has been reported in association with HCM (HGMD), but was also found in several controls (gnomAD). Five clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. - |
Cardiovascular phenotype Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jan 31, 2024 | The c.460C>T (p.R154C) alteration is located in exon 4 (coding exon 4) of the MYL3 gene. This alteration results from a C to T substitution at nucleotide position 460, causing the arginine (R) at amino acid position 154 to be replaced by a cysteine (C). Based on data from gnomAD, the T allele has an overall frequency of 0.001% (4/282804) total alleles studied. The highest observed frequency was 0.008% (2/24964) of African alleles. This variant has been reported in multiple individuals with hypertrophic cardiomyopathy (HCM) (Zou, 2013; Walsh, 2017; Bonaventura, 2019; Ware, 2022; Allouba, 2023; Ambry internal data). This amino acid position is highly conserved in available vertebrate species. This alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, this alteration is classified as likely pathogenic. - |
Hypertrophic cardiomyopathy 8 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Neuberg Centre For Genomic Medicine, NCGM | - | The missense variant c.460C>Tp.Arg154Cys in the MYL3 gene has been reported previously in heterozygous state in individuals affected with hypertrophic cardiomyopathy. Functional studies of this variant indicates a reduction of transactivation activity compared to normal protein Bonaventura et al., 2019; Walsh et al., 2017. This variant is reported with the allele frequency 0.001% in the gnomAD and novel in the 1000 genome database. It is submitted to ClinVar as Uncertain significance Multiple Submissions. The amino acid Arginine at position 154 is changed to a Cysteine changing protein sequence and it might alter its composition and physico-chemical properties. The variant is predicted as damaging by SIFT. The amino acid change p.Arg154Cys in MYL3 is predicted as conserved by GERP++ and PhyloP across 100 vertebrates. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. For these reasons, this variant has been classified as Uncertain significance. - |
Cardiomyopathy Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Feb 09, 2023 | This missense variant replaces arginine with cysteine at codon 154 of the MYL3 protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in individuals affected with hypertrophic cardiomyopathy (PMID: 23283745, 23396983, 27532257, 31110529, 33495597). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Clinical Genetics Laboratory, Skane University Hospital Lund | Feb 27, 2024 | - - |
Primary familial hypertrophic cardiomyopathy Uncertain:1
Uncertain significance, no assertion criteria provided | research | CSER _CC_NCGL, University of Washington | Jun 01, 2014 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at